A Eukaryotic Enzyme That Can Disjoin Dead-end Covalent Complexes Between DNA and Type I Topoisomerases

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1996 Oct 15

PMID 8876170

Citations 207

Authors

S W Yang

A B Burgin Jr

B N Huizenga

C A Robertson

K C Yao

H A NASH

Affiliations

Soon will be listed here.

Abstract

The covalent joining of topoisomerases to DNA is normally a transient step in the reaction cycle of these important enzymes. However, under a variety of circumstances, the covalent complex is converted to a long-lived or dead-end product that can result in chromosome breakage and cell death. We have discovered and partially purified an enzyme that specifically cleaves the chemical bond that joins the active site tyrosine of topoisomerases to the 3' end of DNA. The reaction products made by the purified enzyme on a variety of model substrates indicate that the enzyme cleanly hydrolyzes the tyrosine-DNA phosphodiester linkage, thereby liberating a DNA terminated with a 3' phosphate. The wide distribution of this phosphodiesterase in eukaryotes and its specificity for tyrosine linked to the 3' end but not the 5' end of DNA suggest that it plays a role in the repair of DNA trapped in complexes involving eukaryotic topoisomerase I.

Citing Articles

Untargeted Mutation Triggered by Ribonucleoside Embedded in DNA.

Suzuki T, Yasui K, Komatsu Y, Kamiya H Int J Mol Sci. 2025; 25(24.

PMID: 39769470 PMC: 11679520. DOI: 10.3390/ijms252413708.

TDP1 splice-site mutation causes HAP1 cell hypersensitivity to topoisomerase I inhibition.

Goh C, Bader A, Tran T, Belotserkovskaya R, DAlessandro G, Jackson S Nucleic Acids Res. 2024; 53(2.

PMID: 39660638 PMC: 11754736. DOI: 10.1093/nar/gkae1163.

Cheminformatic Identification of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) Inhibitors: A Comparative Study of SMILES-Based Supervised Machine Learning Models.

Lai C, Kwok A, Wong K J Pers Med. 2024; 14(9).

PMID: 39338235 PMC: 11433629. DOI: 10.3390/jpm14090981.

Tyrosyl-DNA phosphodiesterase 2 (Tdp2) repairs DNA-protein crosslinks and protects against double strand breaks .

Anticevic I, Otten C, Popovic M Front Cell Dev Biol. 2024; 12:1394531.

PMID: 39228401 PMC: 11369425. DOI: 10.3389/fcell.2024.1394531.

From the TOP: Formation, recognition and resolution of topoisomerase DNA protein crosslinks.

Wojtaszek J, Williams R DNA Repair (Amst). 2024; 142:103751.

PMID: 39180935 PMC: 11404304. DOI: 10.1016/j.dnarep.2024.103751.

References

Burgin Jr A, Huizenga B, NASH H . A novel suicide substrate for DNA topoisomerases and site-specific recombinases. Nucleic Acids Res. 1995; 23(15):2973-9. PMC: 307138. DOI: 10.1093/nar/23.15.2973. View

Prinos P, Slack C, Lasko D . 5'phosphorylation of DNA in mammalian cells: identification of a polymin P-precipitable polynucleotide kinase. J Cell Biochem. 1995; 58(1):115-31. DOI: 10.1002/jcb.240580114. View

Lanza A, Tornaletti S, Rodolfo C, Scanavini M, Pedrini A . Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage. J Biol Chem. 1996; 271(12):6978-86. DOI: 10.1074/jbc.271.12.6978. View

Wang J . DNA topoisomerases. Annu Rev Biochem. 1996; 65:635-92. DOI: 10.1146/annurev.bi.65.070196.003223. View

Costin D, POTMESIL M . Preclinical and clinical development of camptothecins. Adv Pharmacol. 1994; 29B:51-72. DOI: 10.1016/s1054-3589(08)61131-x. View

Pommier Y, Tanizawa A, Kohn K . Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol. 1994; 29B:73-92. DOI: 10.1016/s1054-3589(08)61132-1. View

Landy A, Ross W . Viral integration and excision: structure of the lambda att sites. Science. 1977; 197(4309):1147-60. PMC: 1994661. DOI: 10.1126/science.331474. View

Champoux J, McCoubrey Jr W, Been M . DNA structural features that lead to strand breakage by eukaryotic type-I topoisomerase. Cold Spring Harb Symp Quant Biol. 1984; 49:435-42. DOI: 10.1101/sqb.1984.049.01.049. View

Habraken Y, Verly W . Chromatin 3'-phosphatase/5'-OH kinase cannot transfer phosphate from 3' to 5' across a strand nick in DNA. Nucleic Acids Res. 1986; 14(20):8103-10. PMC: 311837. DOI: 10.1093/nar/14.20.8103. View

10.

Matsumoto L, Landy A . Site-specific recombination intermediates trapped with suicide substrates. Cell. 1987; 50(5):779-88. DOI: 10.1016/0092-8674(87)90336-9. View

11.

Nitiss J, Wang J . DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A. 1988; 85(20):7501-5. PMC: 282219. DOI: 10.1073/pnas.85.20.7501. View

12.

Svejstrup J, Christiansen K, Andersen A, Lund K, Westergaard O . Minimal DNA duplex requirements for topoisomerase I-mediated cleavage in vitro. J Biol Chem. 1990; 265(21):12529-35. View

13.

Aris J, Blobel G . Isolation of yeast nuclei. Methods Enzymol. 1991; 194:735-49. DOI: 10.1016/0076-6879(91)94056-i. View

14.

Burgin Jr A, NASH H . Symmetry in the mechanism of bacteriophage lambda integrative recombination. Proc Natl Acad Sci U S A. 1992; 89(20):9642-6. PMC: 50188. DOI: 10.1073/pnas.89.20.9642. View

15.

Pan G, Luetke K, Juby C, Brousseau R, Sadowski P . Ligation of synthetic activated DNA substrates by site-specific recombinases and topoisomerase I. J Biol Chem. 1993; 268(5):3683-9. View

16.

Christiansen K, Knudsen B, Westergaard O . The covalent eukaryotic topoisomerase I-DNA intermediate catalyzes pH-dependent hydrolysis and alcoholysis. J Biol Chem. 1994; 269(15):11367-73. View

17.

Yeh Y, Liu H, Ellis C, Lu A . Mammalian topoisomerase I has base mismatch nicking activity. J Biol Chem. 1994; 269(22):15498-504. View

18.

Chen A, Liu L . DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994; 34:191-218. DOI: 10.1146/annurev.pa.34.040194.001203. View

19.

Bardwell A, Bardwell L, Tomkinson A, Friedberg E . Specific cleavage of model recombination and repair intermediates by the yeast Rad1-Rad10 DNA endonuclease. Science. 1994; 265(5181):2082-5. DOI: 10.1126/science.8091230. View

20.

Pommier Y, Leteurtre F, Fesen M, Fujimori A, Bertrand R, Solary E . Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994; 12(5):530-42. DOI: 10.3109/07357909409021413. View